Loading
A phase 2 trial of IBI363 in melanoma and non-small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
A Study of IBI363 in Subjects with Advanced Solid Malignancies is a phase 2 interventional study registered as NCT06281678 by Innovent Biologics (Suzhou) Co. Ltd., with 178 participants planned, started 2024-04-08 and due to reach its primary completion in 2026-03-01. Interventions recorded: IBI363. Conditions listed: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares IBI363, Innovent Biologics, Melanoma.
Shares IBI363, Innovent Biologics, Colorectal cancer.
Shares IBI363, Innovent Biologics.
Shares IBI363, Innovent Biologics, Melanoma.
Shares IBI363, Innovent Biologics, Non-small-cell lung cancer.
Shares Innovent Biologics, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/